Email this article A CASE OF ACRAL LENTIGINOUS MELANOMA WITH EVALUATION OF С-KIT GENE EXON 11 MUTATION STATUS
- Authors: Komina A.V1, Aksenenko M.B1, Sergeeva O.N1, Kirichenko A.K1, Ruksha T.G.1
-
Affiliations:
- Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-Yasenetsky
- Issue: Vol 20, No 5 (2017)
- Pages: 267-269
- Section: Articles
- URL: https://journals.rcsi.science/1560-9588/article/view/42717
- DOI: https://doi.org/10.18821/1560-9588-2017-20-5-267-269
- ID: 42717
Cite item
Full Text
Abstract
Acral lentiginous melanoma type is characterized by specific clinical and histologic features therefore it requires a special approach to diagnosis and therapy. c-KIT oncogene mutations are frequent in this tumor type accounting up to 23% of all this type melanoma cases. The presence of exons mutations in c-KIT gene indicates therapy of tyrosine kinase inhibitors. The clinical case of acral lentiginous melanoma with the analysis of the mutational status c-KIT 11th exon that is considered as one of the most significant sites, is presented. The functional role of mentioned substitutes was not described previously although tyrosine kinase inhibitors could be effective for such type melanoma patients. Number of mutations, which role in the activity of c-KIT receptor and therapy response have not been studied, is presented.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
A. V Komina
Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-YasenetskyKrasnoyarsk, 660022, Russian Federation
M. B Aksenenko
Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-YasenetskyKrasnoyarsk, 660022, Russian Federation
O. N Sergeeva
Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-YasenetskyKrasnoyarsk, 660022, Russian Federation
A. K Kirichenko
Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-YasenetskyKrasnoyarsk, 660022, Russian Federation
Tatiana G. Ruksha
Krasnoyarsk State Medical University n.a. prof. V.F. Voyno-Yasenetsky
Email: tatyana_ruksha@mail.ru
MD, PhD, DSc., head of Department of pathophysiology of KrasSMU n.a. prof. V.F. Voyno-Yasenetsky, Krasnoyarsk, 660022, Russian Federation Krasnoyarsk, 660022, Russian Federation
References
- Reed R. Acral lentiginous melanoma. In: Hartmann W., Reed R., eds. New concepts in surgical pathology of the skin. New York: Wiley; 1976: 89-90.
- Markovic S.N., Erickson L.A., Rao R.D., Weenig R.H., Pockaj B.A., Bardia A., et al.; Melanoma Study Group of the Mayo Clinic Cancer Center. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin. Proc. 2007; 82(3): 364-80.
- Lee H.Y., Chay W.Y., Tang M.B., Chio M.T., Tan S.H. Melanoma: differences between Asian and Caucasian patients. Ann. Acad. Med. Singapore. 2012; 41(1): 17-20.
- Lee M.W., Koh J.K., Kwon K.S., Kim N.I., Kim S.W., Kim S.N., et al. Clinical and histopathological study of cutaneous melanoma in Korea. Korean J. Dermatol. 2003; 41: 43-47.
- Phan A., Touzet S., Dalle S., Ronger-Savle S., Balme B., Thomas L. Acral lentiginous melanoma: a clinicoprognostic study of 126 cases. Br. J. Dermatol. 2006; 155(3): 561-9.
- Feibleman C.E., Stoll H., Maize J.C. Melanomas of the palm, sole, and nail bed: a clinicopathologic study. Cancer. 1980; 46(11): 2492-504.
- Stalkup J.R., Orengo I.F., Katta R. Controversies in acral lentiginous melanoma. Dermatol. Surg. 2002; 28(11): 1051-9.
- Breslow A. Prognostic factors in the treatment of cutaneous melanoma. J. Cutan. Pathol. 1979; 6(3): 208-12.
- Bristow I.R., Acland K. Acral lentiginous melanoma of the foot and ankle: A case series and review of the literature. J. Foot Ankle Res. 2008; 1(1): 11. doi: 10.1186/1757-1146-1-11.
- Phan A., Dalle S., Touzet S., Ronger-Savlé S., Balme B., Thomas L. Dermoscopic features of acral lentiginous melanoma in a large series of 110 cases in a white population. Br. J. Dermatol. 2010; 162(4): 765-771.
- Nakamura Y., Teramoto Y., Sato S., Yamamoto A. Ch. 5. Current surgical management of acral lentiginous melanoma. In: Murph M., ed. Melanoma - Current Clinical Management and Future Therapeutics. InTech, Chapters published; 2015. doi: 10.5772/59133. Available at: https://www.intechopen.com/books/melanoma-current-clinical-management-and-future-therapeutics/current-surgical-management-of-acral-lentiginous-melanoma (accessed 23 June 2017)
- Ashida A., Takata M., Murata H., Kido K., Saida T. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int. J. Cancer. 2009; 124(4): 862-8.
- Beadling C., Jacobson-Dunlop E., Hodi F.S., Le C., Warrick A., Patterson J., et al. KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. 2008; 14(21): 6821-8.
- Curtin J.A., Busam K., Pinkel D., Bastian B.C. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 2006; 24(26): 4340-6.
- Carvajal R.D. Targeting KIT for treatment of advanced melanoma. Melanoma Lett. 2011; 29(3): 1-4.
- Hodi F.S., Corless C.L., Giobbie-Hurder A., Fletcher J.A., Zhu M., Marino-Enriquez A., et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J. Clin. Oncol. 2013; 31(26): 3182-90.
- Garrido M., Bastian B.C. KIT as a therapeutic target in melanoma. J. Invest. Dermatol. 2010; 130(1): 20-7.
- Forbes S.A., Beare D., Boutselakis H., Bamford S, Bindal N., Tate J., et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017; 45(D1): D777-83. doi: 10.1093/nar/gkw1121.
